The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results.
Karen A. Gelmon
Honoraria - AstraZeneca; Eisai; Novartis; Roche
Maria Vidal
No relevant relationships to disclose
Marie-Paule Sablin
No relevant relationships to disclose
Rosanne Serpanchy
No relevant relationships to disclose
Jesus Soberino
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Diego Villa
No relevant relationships to disclose
Mustapha Zoubir
No relevant relationships to disclose
Ulrich Freudensprung
Employment or Leadership Position - Roche
Jian Xu
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Charlotte Colthorpe
Employment or Leadership Position - Roche
Veronique Dieras
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech